Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
about
Splice Variants of Androgen Receptor and Prostate CancerBiologic and clinical significance of androgen receptor variants in castration resistant prostate cancerProstate Cancer Stem Cells: Research AdvancesInterplay between genomic alterations and androgen receptor signaling during prostate cancer development and progressionAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceEmerging data on androgen receptor splice variants in prostate cancerStilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cellsCharacterization of niphatenones that inhibit androgen receptor N-terminal domainRegistered report: androgen receptor splice variants determine taxane sensitivity in prostate cancerAR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.Androgen receptor splice variants determine taxane sensitivity in prostate cancer.Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.The link between androgen receptor splice variants and castration-resistant prostate cancer.Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.The role of mRNA splicing in prostate cancer.Mouse models of prostate cancer: picking the best model for the question.Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancerProstate cancer characteristics associated with response to pre-receptor targeting of the androgen axisSplicing variants of androgen receptor in prostate cancer.Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer MeetingMethylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancerAndrogen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.Constitutive activity of the androgen receptor.Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerMED1 mediates androgen receptor splice variant induced gene expression in the absence of ligandN-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapyCellular Adhesion Promotes Prostate Cancer Cells Escape from DormancyA profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapiesMechanisms of the androgen receptor splicing in prostate cancer cells.Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.RNA biomarkers to facilitate the identification of aggressive prostate cancer
P2860
Q26740592-AE561666-866D-428F-850D-D07D23B4EFFDQ26858922-3FE4B125-92F2-4A72-995C-A05D467F8F06Q26998435-FDF52E1E-D7C5-41BB-B8AD-35C7E8ED7463Q27022288-309E949E-98CB-4494-8B27-D50A8267FE34Q27853062-64BD2F7C-438D-4339-9E0F-CD50117C1B09Q28076745-4F770C45-96AC-4416-83A9-E3E63B3C5477Q28077830-2061835F-C460-4C7B-879E-D5EF952E8BA0Q28539233-D0EDCF19-5881-447D-9F30-3E03EEFECCDCQ28543404-BE786DDE-0A78-4044-BD03-5DD1E45AE6D4Q28607383-20290A9A-4D01-44FB-9DEC-2CD72BE05F2EQ30544584-3946F8CF-D3EA-4570-93D5-C321FD635DCAQ30554439-2D272CC7-EABF-437E-9F05-28F182AF2BC8Q30572057-C2809345-E361-487A-9720-27B42E10FBA0Q30573685-E79C74BD-B924-4D27-9B06-A1A4304145EDQ30577613-14C0DA66-4E13-4545-B78A-0D95555BDCF8Q30596578-003E67C9-1EB4-4335-94C1-ABF0327D1C71Q30618562-5CA23DBB-ACE7-448D-841A-5EC8D321CC91Q30724105-C4D9DFF0-ADA6-4662-9B8C-130EC284F600Q30831010-D268B566-B990-4CA4-83D8-CC1FCD06BF47Q33688956-022A9D54-DB16-45DE-A90A-6C947C848C33Q33922376-8D82E5B1-01DB-464F-9E68-650636CC6EADQ33940867-B2D941BF-C6A3-4449-86F6-E51CB48E6344Q34364815-E9436CD7-0FE2-4689-9306-3FC44B5D90D0Q34428508-EFF9FAEA-6158-4643-B893-0ECB3D1D2265Q34448143-EB9624D5-C5D2-4CE2-8649-71C3BE02D336Q34617627-A29053EC-3B01-459E-9829-0592EA0FD956Q34663140-6E4D4850-DD89-496D-85C5-72887F459FBAQ34734595-0101D5A0-BB92-42A3-9FAF-7C4F31BB09F1Q34775572-BB85E65F-0536-45DA-A0D8-EED8C688CDDFQ34883636-53DD67A2-087C-4C31-8D3B-E1BBC91464DBQ35150756-69E2F95B-5141-48FF-91E0-B5393D1D95A6Q35238452-D3C5BBC7-B29B-4284-B990-815650DBA873Q35611451-C9D376D4-4477-4430-B8C0-FAE00AD1E74CQ35668319-3FD44456-EFBA-4214-9E0E-590781704F90Q35754996-8FA2AA25-69C4-4E85-86DA-6E212BBF37F9Q35763908-C0FCFD73-6CDA-4DF9-8DEF-5B5EE0485C5FQ35842471-DB8D9297-4B0F-4376-BFB1-8766D4697605Q36005683-6BF19C12-512E-45A4-AEDF-50425215FC29Q36021859-71AEB511-5AA6-444B-87C2-7EE95955FCE8Q36260364-FFC26ACC-50AE-4684-A67E-69FD4A2ADB0F
P2860
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Androgen receptor variants occ ...... ant prostate cancer metastases
@ast
Androgen receptor variants occ ...... ant prostate cancer metastases
@en
Androgen receptor variants occ ...... ant prostate cancer metastases
@en-gb
Androgen receptor variants occ ...... ant prostate cancer metastases
@nl
type
label
Androgen receptor variants occ ...... ant prostate cancer metastases
@ast
Androgen receptor variants occ ...... ant prostate cancer metastases
@en
Androgen receptor variants occ ...... ant prostate cancer metastases
@en-gb
Androgen receptor variants occ ...... ant prostate cancer metastases
@nl
altLabel
Androgen Receptor Variants Occ ...... ant Prostate Cancer Metastases
@en
prefLabel
Androgen receptor variants occ ...... ant prostate cancer metastases
@ast
Androgen receptor variants occ ...... ant prostate cancer metastases
@en
Androgen receptor variants occ ...... ant prostate cancer metastases
@en-gb
Androgen receptor variants occ ...... ant prostate cancer metastases
@nl
P2093
P2860
P3181
P1433
P1476
Androgen receptor variants occ ...... ant prostate cancer metastases
@en
P2093
Colm Morrissey
Funda Vakar-Lopez
Lawrence D True
Melanie Ketchandji
Peter S Nelson
Robert L Vessella
Shihua Sun
Stephen R Plymate
Xiaotun Zhang
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0027970
P407
P577
2011-01-01T00:00:00Z